European Journal of Chemistry 2020, 11(1), 84-90 | doi: https://doi.org/10.5155/eurjchem.11.1.84-90.1970 | Get rights and content






  OPEN ACCESS | PEER-REVIEWED | RESEARCH ARTICLE | DOWNLOAD PDF | VIEW FULL-TEXT PDF | TOTAL VIEWS

Dopamine antagonists for the treatment of drug addiction: PF-4363467 and related compounds


Ana Martinez (1,*) orcid

(1) Departamento de Materiales de Baja Dimensionalidad, Instituto de Investigaciones en Materiales, Universidad Nacional Autonoma de Mexico, Circuito Exterior S/N, Ciudad Universitaria. Coyoacan, CP 04510, CDMX, Mexico
(*) Corresponding Author

Received: 12 Feb 2020 | Revised: 25 Feb 2020 | Accepted: 28 Feb 2020 | Published: 31 Mar 2020 | Issue Date: March 2020

Abstract


Drug addiction refers to an out-of-control and compulsive use of substances, which can reach epidemic magnitudes. It is a health concern throughout the world and has major economic impact. Dopamine receptor agonists and antagonists have been cited as molecular targets for the treatment of drug addiction. In this report, the main idea is to analyze the new D3R/D2R ligands that are proposed for the treatment of drug abuse, in terms of their electron donor/acceptor properties. Substances catalogued as agonists represent good electron donors, whereas antagonists represent good electron acceptors. HOMO and LUMO eigenvalues indicate that more energy is necessary to remove an electron from the antagonists, and likewise more energy is gained when antagonists accept an electron. The combination of two molecules (PF-592379 and PNU-177864) produces a new compound (PF-4363467) with properties that are intermediate. Irrespective of the characteristics of the receptor, the classification of ligands is important, in order to further understanding of the reaction mechanism of these compounds. This may help in the design of new molecules for the treatment of drug addiction.


Keywords


Drug design; Biomolecule; Antipsychotics; Donor acceptor map; Computational chemistry; Density functional calculations

Full Text:

PDF /    /


DOI: 10.5155/eurjchem.11.1.84-90.1970

Links for Article


| | | | | | |

| | | | | | |

Related Articles




Article Metrics

This Abstract was viewed 443 times | PDF Article downloaded 19 times

Funding information


Universidad Nacional Autonoma de Mexico (CONACYT) Coyoacan, Mexico.

References

[1]. National Institute on Drug Abuse, Drugs, Brains, and Behaviour: The Science of Addiction, NIH Publication: USA, 2014.

[2]. Singh, J.; Gupta, P. Inter. J. Indian Psych. 2017, 5, 2348-5396.

[3]. Medina-Mora, M. E.; Cravioto, P.; Ortiz, A.; Kuri, P.; Villatoro, J. Bull. Narcotics. 2003, 55, 105-119.

[4]. Wager, T. T.; Chandrasekaran, R. Y.; Bradley, J.; Rubitski, D.; Berke, H.; Mente, S.; Butler, T.; Doran, A.; Chang, C.; Fisher, K.; Knafels, J.; Liu, S.; Ohren, J.; Marconi, M.; DeMarco, G.; Sneed, B.; Walton, K.; Horton, D.; Rosado, A.; Mead, A. ACS Chem. Neurosci. 2014, 5, 1253-1265.
https://doi.org/10.1021/cn500201x

[5]. Sokoloff, P.; Giros, B.; Martres, M. P.; Bouthenet, M. L.; Schwartz, J. C. Nature 1990, 347, 146-151.
https://doi.org/10.1038/347146a0

[6]. Newman, A. H.; Grundt, P.; Nader, M. A. J. Med. Chem. 2005, 48, 3663-3679.
https://doi.org/10.1021/jm040190e

[7]. Heidbreder, C. A.; Newman, A. H. Ann. NY Acad. Sci. 2010, 1187, 4-34.
https://doi.org/10.1111/j.1749-6632.2009.05149.x

[8]. Cho, D.; Zheng, M.; Kim, K. M. Arch. Pharmacal. Res. 2010, 33, 1521-1538.
https://doi.org/10.1007/s12272-010-1005-8

[9]. Keck, T. M.; John, W. S.; Czoty, P. W.; Nader, M. A.; Newman, A. H. J. Med. Chem. 2015, 58, 5361-5380.
https://doi.org/10.1021/jm501512b

[10]. Micheli, F.; Arista, L.; Bonanomi, G.; Blaney, F. E.; Braggio, S.; Capelli, A. M.; Checchia, A.; Damiani, F.; Di-Fabio, R.; Fontana, S.; Gentile, G.; Griffante, C.; Hamprecht, D.; Marchioro, C.; Mugnaini, M.; Piner, J.; Ratti, E.; Tedesco, G.; Tarsi, L.; Terreni, S.; Worby, A.; Ashby Jr. , C. R.; Heidbreder, C. J. Med. Chem. 2010, 53, 374-391.
https://doi.org/10.1021/jm901319p

[11]. Mugnaini, M.; Iavarone, L.; Cavallini, P.; Griffante, C.; Oliosi, B.; Savoia, C.; Beaver, J.; Rabiner, E. A.; Micheli, F.; Heidbreder, C.; Andorn, A.; Pich, E. M.; Bani, M. Neuropsychopharmacology 2013, 38, 302-312.
https://doi.org/10.1038/npp.2012.171

[12]. Pilla, M.; Perachon, S.; Sautel, F.; Garridok, F.; Mannk, A.; Wermuthk, C. G.; Schwartz, J. C.; Everitt, B. J.; Sokoloff, P. Nature 1999, 400, 371-375.
https://doi.org/10.1038/22560

[13]. Le Foll, B.; Goldberg, S. R.; Sokoloff, P. Neuropharmacology 2005, 49, 525-541.
https://doi.org/10.1016/j.neuropharm.2005.04.022

[14]. Roman, V.; Gyertyan, I.; Saghy, K.; Kiss, B.; Szombathelyi, Z. Psychopharmacology 2013, 226, 285-293.
https://doi.org/10.1007/s00213-012-2906-7

[15]. Li, P.; Snyder, G. L.; Vanover, K. E. Curr. Top Med. Chem. 2016, 16, 3385-3403.
https://doi.org/10.2174/1568026616666160608084834

[16]. Wickelgren, I. Science 1998, 281, 1264-1265.
https://doi.org/10.1126/science.281.5381.1264

[17]. Chauhan, A.; Mittal, A.; Arora, P. K. J. Pharm. Sci. Res. 2013, 4, 184-204.

[18]. Martinez, A.; Ibarra, I. A.; Vargas, R. PlosONE 2019, 14, e0224691.
https://doi.org/10.1371/journal.pone.0224691

[19]. Martinez, A.; Vargas, R. J. Pharm. Pharmaceut. Res. 2018, 1, 1-8.

[20]. Kiss, B.; Horvath, A.; Zs, N.; Schmidt, E.; Laszlovszky, I.; Gy, B.; Fazekas, K.; Hornok, K.; Sz, O.; Gyertyan, I.; Agai-Csongor, E.; Gy, D.; Tihanyi, K.; Adham, N.; Zs, S. J. Pharmacol. Exp. Ther. 2010, 333, 328-340.
https://doi.org/10.1124/jpet.109.160432

[21]. Gyertyan, I.; Kiss, B.; Saghy, K.; Laszy, J.; Gy, S.; Szabados, T.; Gemesi, L. I.; Pasztor, G.; Zajer-Balazs, M.; Kapas, M.; Agai-Csongor, E.; Gy, D.; Tihanyi, K.; Zs, S. Neurochem. In. 2011, 59, 925-935.
https://doi.org/10.1016/j.neuint.2011.07.002

[22]. McCormack, P. L. Drugs 2015, 75, 2035-2043.
https://doi.org/10.1007/s40265-015-0494-7

[23]. Wager, T. T.; Chappie, T.; Horton, D.; Chandrasekaran, R. Y.; Samas, B.; Dunn-Sims, E. R.; Hsu, C.; Nawreen, N.; Vanase-Frawley, M. A.; O'Connor, R. E.; Schmidt, C. J.; Dlugolenski, K.; Stratman, N. C.; Majchrzak, M. J.; Kormos, B. L.; Nguyen, D. P.; Sawant-Basak, A.; Mead, A. N. ACS Chem. Neurosci. 2017, 8, 165-177.
https://doi.org/10.1021/acschemneuro.6b00297

[24]. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, Jr. , J. A.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; P. Hratchian, H.; Cross, J. B.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A., Gaussian 09, revision A. 02, Gaussian, Inc. , Wallingford CT, 2009.

[25]. Zhao, Y.; Truhlar, D. G. Theor. Chem. Acc. 2008, 120, 215-241.
https://doi.org/10.1007/s00214-007-0310-x

[26]. Petersson, G. A.; Bennett, A.; Tensfeldt, T. G.; Al-Laham, M. A.; Shirley, W. A. J. Chem. Phys. 1988, 89, 2193-2218.
https://doi.org/10.1063/1.455064

[27]. Petersson, G. A.; Al-Laham, M. A. J. Chem. Phys. 1991, 94, 6081-6090.
https://doi.org/10.1063/1.460447

[28]. McLean, A. D.; Chandler, G. S. J. Chem. Phys. 1980, 72, 5639-5648.
https://doi.org/10.1063/1.438980

[29]. Raghavachari, K.; Binkley, J. S.; Seeger, R.; Pople, J. A. J. Chem. Phys. 1980, 72, 650-654.
https://doi.org/10.1063/1.438955

[30]. Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. J. Phys. Chem. B. 2009, 113, 6378-6396.
https://doi.org/10.1021/jp810292n

[31]. Islam, N.; Ghosh, D. C. Eur. J. Chem. 2010, 1, 83-89.
https://doi.org/10.5155/eurjchem.1.2.83-89.26

[32]. Islam, N. Eur. J. Chem. 2011, 2, 448-454.
https://doi.org/10.5155/eurjchem.2.4.448-454.94

[33]. Gazquez, J. L.; Cedillo, A.; Vela. A. J. Phys. Chem. A. 2007, 111, 1966-1970.
https://doi.org/10.1021/jp065459f

[34]. Gazquez, J. L. J. Mex. Chem. Soc. 2008, 52, 3-10.

[35]. Martinez, A.; Rodriguez-Girones, M. A.; Barbosa, A.; Costas, M. J. Phys. Chem. A. 2008, 112, 9037-9042.
https://doi.org/10.1021/jp803218e

[36]. Martinez, A. J. Phys. Chem. B. 2009, 113. 4915-4921.
https://doi.org/10.1021/jp8102436

[37]. Ceron-Carrasco, J. P.; Bastida, A.; Requena, A.; Zuniga, J.; Miguel, B. J. Phys. Chem. B. 2010, 114, 4366-4372.
https://doi.org/10.1021/jp911846h

[38]. Pillegowda, M.; Periyasamy, G. Comput. Theor. Chem. 2018, 1129, 26-36.
https://doi.org/10.1016/j.comptc.2018.02.012

[39]. Alfaro, R. A. D.; Gomez-Sandoval, Z.; Mammino, L. J. Mol. Model. 2014, 20, 2337, 1-11.
https://doi.org/10.1007/s00894-014-2337-y

[40]. Duarte, C.; Lefebvre, C.; Chaperon, F.; Hamon, M.; Thiébot, M. H. Neuropsychopharmacology 2003, 28, 1903-1915.
https://doi.org/10.1038/sj.npp.1300276

[41]. Maramai, S.; Gemma, S.; Brogi, S.; Campiani, G.; Butini, S.; Stark, H.; Brindisi, M. Front. Neurosci. 2016, 10, 1-13, Article 451.
https://doi.org/10.3389/fnins.2016.00451

[42]. Garcia-Ladona, F. J.; Cox. B. F. CNS Drug Rev. 2003, 9, 141-158.
https://doi.org/10.1111/j.1527-3458.2003.tb00246.x

[43]. Wicke, K.; Garcia-Ladona, J. Eur. J. Pharmacol. 2001, 424, 85-90.
https://doi.org/10.1016/S0014-2999(01)01054-8

[44]. Xi, Z. X.; Gardner, E. L. CNS Drug Rev. 2007, 13, 240-259.
https://doi.org/10.1111/j.1527-3458.2007.00013.x

How to cite


Martinez, A. Eur. J. Chem. 2020, 11(1), 84-90. doi:10.5155/eurjchem.11.1.84-90.1970
Martinez, A. Dopamine antagonists for the treatment of drug addiction: PF-4363467 and related compounds. Eur. J. Chem. 2020, 11(1), 84-90. doi:10.5155/eurjchem.11.1.84-90.1970
Martinez, A. (2020). Dopamine antagonists for the treatment of drug addiction: PF-4363467 and related compounds. European Journal of Chemistry, 11(1), 84-90. doi:10.5155/eurjchem.11.1.84-90.1970
Martinez, Ana. "Dopamine antagonists for the treatment of drug addiction: PF-4363467 and related compounds." European Journal of Chemistry [Online], 11.1 (2020): 84-90. Web. 29 May. 2020
Martinez, Ana. "Dopamine antagonists for the treatment of drug addiction: PF-4363467 and related compounds" European Journal of Chemistry [Online], Volume 11 Number 1 (31 March 2020)

The other citation formats (EndNote | Reference Manager | ProCite | BibTeX | RefWorks) for this article can be found online at: How to cite item


DOI Link: https://doi.org/10.5155/eurjchem.11.1.84-90.1970

| | | | | | |

| | | | | |

Save to Zotero Save to Mendeley



European Journal of Chemistry 2020, 11(1), 84-90 | doi: https://doi.org/10.5155/eurjchem.11.1.84-90.1970 | Get rights and content

Refbacks

  • There are currently no refbacks.




Copyright (c) 2020 Authors

Creative Commons License
This work is published and licensed by Atlanta Publishing House LLC, Atlanta, GA, USA. The full terms of this license are available at http://www.eurjchem.com/index.php/eurjchem/pages/view/terms and incorporate the Creative Commons Attribution-Non Commercial (CC BY NC) (International, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0). By accessing the work, you hereby accept the Terms. This is an open access article distributed under the terms and conditions of the CC BY NC License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited without any further permission from Atlanta Publishing House LLC (European Journal of Chemistry). No use, distribution or reproduction is permitted which does not comply with these terms. Permissions for commercial use of this work beyond the scope of the License (http://www.eurjchem.com/index.php/eurjchem/pages/view/terms) are administered by Atlanta Publishing House LLC (European Journal of Chemistry).


© Copyright 2010 - 2020  Atlanta Publishing House LLC All Right Reserved.

The opinions expressed in all articles published in European Journal of Chemistry are those of the specific author(s), and do not necessarily reflect the views of Atlanta Publishing House LLC, or European Journal of Chemistry, or any of its employees.

Copyright 2010-2020 Atlanta Publishing House LLC. All rights reserved. This site is owned and operated by Atlanta Publishing House LLC whose registered office is 2850 Smith Ridge Trce Peachtree Cor GA 30071-2636, USA. Registered in USA.

hatay escort hatay escort corlu escort corum escort burgaz escort giresun escort aydin escort ordu escort erzincan escort hatay escort sivas escort rize escort edirne escort aksaray escort kibris escort isparta escort erzurum escort tekirdag escort usak escort urfa escort kastamonu escort kibris escort manisa escort giresun escort urfa escort nevsehir escort sivas escort yalova escort ordu escort hatay escort yalova escort amasya escort kayseri escort ordu escort maras escort canakkale escort yalova escort balikesir escort manisa escort urfa escort mugla escort trabzon escort bolu escort corlu escort diyarbakir escort isparta escort kutahya escort elazig escort erzurum escort sakarya escort afyon escort kutahya escort konya escort agri escort cesme escort sinop escort sivas escort konya escort kibris escort adapazari escort luleburgaz escort adana escort kibris escort rize escort sakarya escort alanya escort isparta escort burdur escort konya escort bitlis escort canakkale escort sivas escort amasya escort mus escort aydin escort van escort yalova escort kastamonu escort mardin escort bolu escort afyon escort sakarya escort isparta escort tokat escort trakya escort bayburt escort urfa escort mardin escort